Core Viewpoint - UBS reports that Innovent Biologics (01801) has six new products and a new indication for sintilimab included in the latest National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Innovent Biologics has been officially included in the Hang Seng Index as of today [1] - UBS maintains a "Buy" rating with a target price of HKD 137.4 [1] Group 1 - The new products targeting IGF-1R, EGFR, BTK, ROS1, KRAS G12C, and RET are expected to see rapid sales growth by 2026 [1] - The inclusion of teriparatide for diabetes in the insurance list positively impacts the expected launch of masitinib in 2026, although price adjustments need to be monitored [1] - Inclusion in the Hang Seng Index is anticipated to further enhance liquidity for the company's stock [1]
瑞银：维持信达生物(01801)“买入”评级 目标价137.4港元